SOP Guide for Pharma

SOP for Corrective and Preventive Actions (CAPA) in Transdermal Patches Production

SOP for Corrective and Preventive Actions (CAPA) in Transdermal Patches Production

Standard Operating Procedure for Corrective and Preventive Actions (CAPA) in Transdermal Patches Production

1) Purpose

The purpose of this SOP is to establish a standardized procedure for identifying, implementing, and documenting corrective and preventive actions (CAPA) to address quality issues, deviations, and non-conformances in the production of transdermal patches, ensuring continuous improvement and regulatory compliance.

2) Scope

This SOP applies to all personnel involved in the production, quality control, and quality assurance of transdermal patches, as well as any other departments that may contribute to or be affected by CAPA activities.

3) Responsibilities

The Quality Assurance (QA) Department is responsible for overseeing the CAPA process. All personnel are responsible for identifying potential quality issues and participating in the implementation and documentation of CAPA measures.

4) Procedure

4.1 Identification of Issues

4.2 CAPA Assessment and Planning

4.3 Investigation and Root Cause Analysis

4.4 Implementation of Corrective Actions

4.5 Implementation of Preventive Actions

4.6 Review and Approval

4.7 Documentation and Trending

5) Abbreviations, if any

SOP: Standard Operating Procedure
QA: Quality Assurance
QC: Quality Control
CAPA: Corrective and Preventive Actions
FMEA: Failure Mode and Effects Analysis

6) Documents, if any

CAPA Request Form
CAPA Report
CAPA Log
Batch Records
Investigation Documentation

7) Reference, if any

ICH Q10: Pharmaceutical Quality System
21 CFR Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals
FDA Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP Regulations

8) SOP Version

Version 1.0

Exit mobile version